Store-Bought Peanut Butter Protocol Shows High Efficacy for High-Threshold Peanut Allergy
NIAID/NIH immunotherapy uses measured Peanut Butter to raise allergy thresholds, with specialist-guided dosing and safety nuances.
New data from the CAFETERIA study, a phase 2 trial funded by the National Institutes of Health (NIH) and published in NEJM Evidence, suggests a pragmatic oral
The study found 100% of children with a "high-threshold" peanut allergy—those who could initially tolerate at least half a peanut—were able to consume 9 grams of peanut protein, equivalent to three tablespoons of peanut butter, without an allergic reaction after approximately 18 months of treatment.
“Children with high-threshold peanut allergy couldn’t participate in previous food allergy treatment trials, leaving them without opportunities to explore treatment options,” stated Jeanne Marrazzo, MD, MPH, National Institute of Allergy and Infectious Diseases (NIAID) director. “Today’s report focuses on this population and shows that a very safe and accessible form of therapy could be liberating for many of these children and their families.”
While previous FDA-approved food allergy treatments focused on low-threshold patients who react to trace amounts, this protocol addresses an estimated 800,000 US children with high-threshold allergies who previously had no management strategy other than strict avoidance.
The trial involved 73 children aged 4 to 14 years, utilizing a protocol began with a daily dose of 1/8 teaspoon of peanut butter, gradually escalating to 1 tablespoon or equivalent peanut products under medical supervision. All 32 treated and 3 out of 30 avoiders (10%) tolerated 9043 mg. Sustained unresponsiveness occurred in 68.4% (26/38) on P-OIT versus 8.6% (3/35) tolerating 9043 mg among those avoiding.1,2
Safety data from the trial were encouraging; no children required epinephrine for severe reactions during home dosing, and only one participant required it during a supervised clinic visit. Furthermore, 86.7% of treated children who participated in a final food challenge maintained their tolerance even after 8 weeks of avoiding peanuts entirely, achieving what researchers define as sustained unresponsiveness.
Despite the accessibility of using supermarket products, experts urge caution regarding clinical implementation. Lead investigator Scott Sicherer, MD, director of the Elliot and Roslyn Jaffe Food Allergy Institute, notes using non-FDA-approved commercial products requires a "special agreement" and a deep understanding of protein variability. For example, the protein content in chocolate-coated peanuts or different brands of peanut butter can vary significantly, necessitating medical supervision during any product transitions.
Additionally, clinicians must account for augmentation factors such as active asthma, viral infections, or physical exertion—which can lower a patient's reaction threshold and require immediate dose adjustments. Because of these nuances, current recommendations suggest OIT management remain with allergy specialists. While this "real journey" for patients may eventually be translatable to primary care as more safety data emerges, the complexity of dosing and symptom management currently necessitates a specialist-led approach.
References:
- Therapy helps peanut-allergic kids tolerate tablespoons of peanut butter. National Institutes of Health (NIH). Published February 10, 2025. Accessed February 27, 2026.
https://www.nih.gov/news-events/news-releases/therapy-helps-peanut-allergic-kids-tolerate-tablespoons-peanut-butter - Sicherer SH, Bunyavanich S, Berin MC, et al. Peanut Oral Immunotherapy in Children with High-Threshold Peanut Allergy. NEJM Evidence. Published online February 10, 2025. doi: https://doi.org/10.1056/evidoa2400306
